+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Selective approach to radionuclide-guided sentinel lymph node biopsy in high-risk ductal carcinoma in situ of the breast



Selective approach to radionuclide-guided sentinel lymph node biopsy in high-risk ductal carcinoma in situ of the breast



Nuclear Medicine Communications 32(11): 1084-1087



Ductal carcinoma in situ (DCIS) currently represents approximately 15-25% of all breast cancers detected. Although inherently a noninvasive disease, occult invasive disease can be found at definitive histology. The role of sentinel lymph node (SLN) biopsy in DCIS is still unclear. The aim of this study was to evaluate the clinical usefulness of SLN biopsy and the incidence of SLN metastases in selected patients with high-risk DCIS, who are at highest risk for being upstaged to invasive carcinoma. Twenty-three high-risk patients with DCIS proven on core biopsy (mean age, 50 years; median age, 48 years; age range, 37-78 years) were included in the study. SLN scintigraphy was performed 2-4 h before surgery by injecting Tc-99m-labeled nanocolloid intradermally in the periareolar region. The first lymph node to appear on the scan was labeled as SLN and was marked on the skin by using a γ probe. The lymph node was explored in the axilla using a γ probe. The SLN was identified in all patients (100% success rate). Of 23 cases of DCIS on core biopsy, seven patients (30%) were shown to have invasive ductal carcinoma on final histological specimen. Among these seven patients, three had minimal invasive carcinoma (<1 cm) and none of these patients had positive SLN for metastases. Among 23 cases, only one patient with (4%) SLN was positive for metastasis despite histopathological diagnosis of pure DCIS. Although the study population is small, our findings suggest that patients with high-risk DCIS have an increased risk of invasive disease, as approximately one-third of these patients had invasive component at the time of definitive operative procedure. Furthermore, the study also suggests that SLNB appears to be reliable in identifying axillary lymph nodes status of these patients.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055693288

Download citation: RISBibTeXText

PMID: 21862942

DOI: 10.1097/MNM.0b013e328349eafc


Related references

Predictors of invasion in patients with core-needle biopsy-diagnosed ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy in ductal carcinoma in situ. Cancer 107(8): 1760-1768, 2006

Predictors of invasive breast cancer in mammographically detected microcalcification in patients with a core biopsy diagnosis of flat epithelial atypia, atypical ductal hyperplasia or ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy. Pathology, Research and Practice 208(4): 217-220, 2012

Sentinel lymph node biopsy in patients with pure and high-risk ductal carcinoma in situ of the breast. Tumori 95(6): 706-711, 2010

Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. Journal of the American College of Surgeons 200(4): 516-526, 2005

Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma-in-situ with microinvasion?. Annals of Surgical Oncology 7(9): 636-642, 2000

Role of sentinel lymph node biopsy in high-risk ductal carcinoma in situ patients. American Journal of Surgery 194(2): 172-175, 2007

Sentinel Lymph Node Biopsy Should Be Included with the Initial Surgery for High-Risk Ductal Carcinoma-In-Situ. International Scholarly Research Notices 2014: 624185, 2014

Sentinel lymph node biopsy in ductal carcinoma in situ of the male breast. Breast Journal 11(2): 154, 2005

Indication for sentinel lymph node biopsy for breast cancer when core biopsy shows ductal carcinoma in situ. American Journal of Surgery 202(1): 59-65, 2011

Sentinel lymph node biopsy is not warranted following a core needle biopsy diagnosis of ductal carcinoma in situ (DCIS) of the breast. Breast 24(3): 197-200, 2016

Sentinel lymph node biopsy is not necessary in patients diagnosed with ductal carcinoma in situ of the breast by stereotactic vacuum-assisted biopsy. Breast Cancer 23(2): 190-194, 2016

Ductal carcinoma in situ of the breast with microinvasion. Role of sentinel lymph node biopsy. Gynecologie, Obstetrique and Fertilite 35(4): 317-322, 2007

Value of sentinel lymph node biopsy in breast ductal carcinoma in situ upstaged to invasive carcinoma. Breast Journal 14(1): 55-60, 2008

Sentinel lymph node biopsy as a tool for the staging of ductal carcinoma in situ in patients with breast carcinoma. Surgery Today 32(2): 99-103, 2002

Clinical applications of sentinel lymph node biopsy in ductal carcinoma in situ of the breast: a dilemma. Tohoku Journal of Experimental Medicine 224(1): 1-5, 2011